Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance)

Jansson-Knodell, Claire; Foster, Nathan R.; Sargent, Daniel J.; Limburg, Paul J.; Thibodeau, Stephen N.; Smyrk, Thomas C.; Sinicrope, Frank A.; Jahagirdar, Balkrishna; Goldberg, Richard M.; Alberts, Steven R.

doi:10.21037/jgo.2016.12.13

Cited by 8 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this did not lead to differences in CSS and OS in our adjusted analyses. Our finding of no association between family history of CRC and survival in patients with CRC is consistent with reports from five previous studies conducted in population‐based cohorts or within a clinical trial . The most robust study was conducted within the CCFR which reported no association between family history of CRC and OS, after adjusting for microsatellite instability (MSI) status or tumor site .…”

Section: Discussionsupporting

confidence: 89%

“…Although we are unable to account for MSI and other mutation status, for example, V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) due to lack of information, several studies suggested that adjustment for MSI or mismatch repair (MMR) status and mutation status had minimal impact on the null associations [18,25]. Among stage III resected colon cancer patients treated with adjuvant chemotherapy in a randomized controlled trial (N0147), having a family history of CRC did not impact disease free survival and OS, after adjustment for other predictors of mortality including KRAS or BRAF mutations and MMR status [25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies

et al. 2018

View full text Add to dashboard Cite

A family history of colorectal cancer (CRC) in first‐degree relatives (FDRs) increases the risk of CRC. However, the influence of family history on survival among CRC patients remains unclear. We conducted a pooled analysis of survival in 5010 incident CRC cases. Cox proportional hazards models were used to estimate the association of family history with overall survival (OS) and CRC‐specific survival (CSS). We also assessed the impact of the number of affected FDRs and age at CRC diagnosis in the affected FDRs on survival. Among CRC cases, 819 (16%) patients reported a family history of CRC. There were 1580 total deaths over a median follow‐up of 4.6 years, of which 1046 (66%) deaths were due to CRC. Having a family history of CRC was not associated with OS [hazard ratio (HR), 1.03; 95% confidence interval (CI), 0.89–1.19] or CSS (HR, 1.13; 95% CI, 0.95–1.36)]. There were no associations between the number of affected relatives or age at CRC diagnosis of the affected relative with survival (all P trend > 0.05). However, a family history of CRC did confer worse CSS in patients diagnosed with distal colon cancer (HR, 1.45, 95% CI, 1.03–2.04). A family history of CRC was generally not associated with survival after CRC diagnosis. However, having a family history of CRC was associated with worse CRC prognosis in individuals with distal colon cancer, suggesting a possible genetic predisposition with distinct pathogenic mechanism that may lead to worse survival in this group.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Relatively common but less penetrant genetic predisposition may influence survival as well as increased CRC risk in familial CRC patients. Some previous studies suggested that FH of CRC is associated with higher frequency of MSI-high [21], and the beneficial effect of FH on CRC survival was prominent in right colon [12,15,16]. However, the association of MSI status on prognosis was not consistent between studies [14], and MSI status was not different by FH in our study.…”

Section: Discussioncontrasting

confidence: 86%

“…However, the influence of FH of CRC on CRC recurrence and survival remains uncertain, and the results from studies are inconsistent. Several studies reported the negligible impact of FH of CRC and survival [10–12]. Some studies reported improved survival [13–16], whereas the others showed worse prognosis in patients with a FH of CRC [17,18].…”

Section: Introductionmentioning

confidence: 99%

Association of Family History With Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients With Colorectal Cancer

Park

Cheon

et al. 2019

J Cancer Prev

View full text Add to dashboard Cite

Background The influence of family history (FH) on cancer recurrence and survival among patients with established colorectal cancer (CRC) remains uncertain. This study aimed to evaluate the association of FH with cancer recurrence, survival, and the incidence of colorectal adenomas in patients with CRC. Methods Consecutive patients with stage III CRC diagnosed between 2004 and 2009 and followed-up in Severance Hospital were retrospectively enrolled and followed until December 2014. Overall survival (OS) and disease-free survival (DFS) according to FH of CRC or colorectal neoplasm were evaluated using Cox proportional hazards regression and Kaplan–Meier curve. Results Among analyzed 979 patients, 69 (7.0%) was identified as having a FH of CRC in a first-degree relative. During a median follow-up of 9.6 years, mortality occurred in 14 of 69 patients (20.3%) with a FH of CRC and 348 of 910 patients (38.2%) without a FH. Compared with patients without a FH, a first-degree FH of CRC, first or second-degree FH of CRC, and first-degree FH of colorectal neoplasm (CRC or polyps) were associated with a significant reduction in the risk of overall mortality, with adjusted hazard ratios (HRs) of 0.52 (95% CI, 0.29–0.92), 0.51 (95% CI, 0.30–0.88), and 0.48 (95% CI, 0.28–0.82), respectively. However, DFS improvement was significant only when the definition of FH was FH of colorectal neoplasm (adjusted HR 0.57; 95% CI, 0.36–0.89). The incidence of adenoma and advanced adenoma was not different according to the FH. Conclusions Among patients with stage III CRC receiving curative surgery, a FH of colorectal neoplasm was associated with a reduction in cancer recurrence and mortality. The larger scaled studies are needed.

show abstract

“…More than 1 million people in the world suffer from this form of cancer, and over 600,000 people die from it each year, [Basu et al, ]. It has been estimated that 134,490 people in 2016 would be newly diagnosed with CRC in the United States which eventually would claim 49,190 lives [Jansson‐Knodell et al, ]. Though CRC could occur at any age, the the greatest risk for CRC correlates with individuals who are over 50 years old [Abernathy et al, ].…”

mentioning

confidence: 99%

Retracted: Effects of shRNA‐Mediated Silencing of PKM2 Gene on Aerobic Glycolysis, Cell Migration, Cell Invasion, and Apoptosis in Colorectal Cancer Cells

Yan

Zhang

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

This study aims to explore the effects of shRNA-mediated silencing on Pyruvate kinase type M2 (PKM2) gene during aerobic glycolysis in colorectal cancer (CRC) cells. CRC tissues and adjacent normal tissues were obtained from 136 patients diagnosed with qRT-PCR, Western blotting, and immunohistochemistry (IHC) were performed to detect mRNA and protein expressions of PKM2. CRC cells were divided into a blank, vector, and PKM2-shRNA groups. Hexokinase (HK) and PKM2 activity were both determined by glucose-6-phosphate dehydrogenase (G-6-PD) coupled colorimetric assay and enzyme coupling rate method. The extracellular lactate concentration was measured by ultraviolet spectrophotometer and caspase activity was measured using spectrophotometry. The proliferation, cell cycle, apoptosis, invasion, and migration of CRC cells were detected by cell counting kit-8 (CCK-8) assay, flow cytometry, transwell assay, and scratch test. Three groups of nude mice were injected with 0.2 mL single-cell suspension from the blank, vector, and PKM2-shRNA groups, respectively. PKM2 protein content in CRC tissues was higher than that in adjacent normal tissues. Results showed that the PKM2-shRNA group exhibited significantly lower mRNA and protein expressions of PKM2, decreased PKM2 activity, reduced lactate metabolism level, increased cell apoptosis rate, elevated caspase-3 and caspase-9 activity, weakened proliferation, and a reduction in cell invasion and migration ability compared to the vector and blank groups. The optical density (OD) value was lower in the PKM2-shRNA group than in the blank and vector groups. These findings indicate that shRNA-mediated silencing of PKM2 gene promotes apoptosis and inhibits aerobic glycolysis, proliferation, migration, and invasion in CRC cells. J. Cell. Biochem. 118: 4792-4803, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Family history of colorectal cancer and its impact on survival in patients with resected stage III colon cancer: results from NCCTG Trial N0147 (Alliance)

Cited by 8 publications

References 33 publications

Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies

Association of family history and survival in patients with colorectal cancer: a pooled analysis of eight epidemiologic studies

Association of Family History With Cancer Recurrence, Survival, and the Incidence of Colorectal Adenoma in Patients With Colorectal Cancer

Retracted: Effects of shRNA‐Mediated Silencing of PKM2 Gene on Aerobic Glycolysis, Cell Migration, Cell Invasion, and Apoptosis in Colorectal Cancer Cells

Contact Info

Product

Resources

About